Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare. | June 2, 2023
Pivotal Phase 3 IMPALA-2 Trial Remains On-Track
Company expects trial to be fully enrolled in June 2023, on-track to report top line data by end of 2Q 2024
48-week placebo-controlled trial is. | May 15, 2023
Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On March 29, 2023, the. | March 31, 2023